URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.

March 15, 2026 expert reaction to conference abstract comparing prostate cancer and breast cancer screening programmes, being presented at the European Association of Urology Cong ...

The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ...

The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.

Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) procedures in Arizona using the Vanquish® Water ...

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

The new funding will help the cluster build on initial milestones and to prepare for clinical applications, particularly in cancer.

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...